Literature DB >> 14732733

Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease.

Willa A Hsueh1, Dennis Bruemmer.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPARgamma is expressed by macrophages, endothelial cells, and vascular smooth muscle cells. It regulates gene expression of key proteins involved in lipid metabolism, vascular inflammation, and proliferation contributing to atherogenesis and postangioplasty restenosis. The discovery of synthetic ligands for PPARgamma has led to significant enhancement of our understanding of the mechanism of their ligand-dependent activation and subsequent biological effects, particularly with respect to the role of PPARgamma in vascular pathophysiology. The thiazolidinedione PPARgamma agonists not only improve insulin resistance in patients with type II diabetes but also exert a broad spectrum of antiatherogenic effects in vitro and in animal models of atherosclerosis. In this review, we summarize the important role of PPARgamma as a molecular target for thiazolidinediones and its implications for the control of vascular inflammation and proliferation for the cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732733     DOI: 10.1161/01.HYP.0000113626.76571.5b

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

1.  Functional genomics of PPAR-gamma in human immunomodulatory cells.

Authors:  Deepak Kaul; Paras K Anand; Amit Khanna
Journal:  Mol Cell Biochem       Date:  2006-04-22       Impact factor: 3.396

Review 2.  Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes.

Authors:  A Enrique Caballero
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

3.  The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation.

Authors:  Takashi Nomiyama; Takafumi Nakamachi; Florence Gizard; Elizabeth B Heywood; Karrie L Jones; Naganari Ohkura; Ryuzo Kawamori; Orla M Conneely; Dennis Bruemmer
Journal:  J Biol Chem       Date:  2006-08-31       Impact factor: 5.157

Review 4.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Determination of PPARγ activity in adipose tissue and spleen.

Authors:  Siu-Lung Chan; Marilyn J Cipolla
Journal:  J Immunoassay Immunochem       Date:  2012

6.  Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension.

Authors:  Lili Zhang; Peng Xie; Jingzhou Wang; Qingwu Yang; Chuanqin Fang; Shuang Zhou; Jingcheng Li
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

Review 7.  PPAR ligands: potential therapies for metabolic syndrome.

Authors:  Taro E Akiyama; Peter T Meinke; Joel P Berger
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

8.  Profilin-1 is expressed in human atherosclerotic plaques and induces atherogenic effects on vascular smooth muscle cells.

Authors:  Evren Caglayan; Giulio R Romeo; Kai Kappert; Margarete Odenthal; Michael Südkamp; Simon C Body; Stanton K Shernan; Daniel Hackbusch; Marius Vantler; Andrius Kazlauskas; Stephan Rosenkranz
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

9.  Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

Authors:  G-H Hao; X-L Niu; D-F Gao; J Wei; N-P Wang
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

10.  Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.

Authors:  Shirley K Knauer
Journal:  J Oncol       Date:  2009-09-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.